Insulet Past Earnings Performance
Past criteria checks 5/6
Insulet has been growing earnings at an average annual rate of 52.3%, while the Medical Equipment industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 19.9% per year. Insulet's return on equity is 28.2%, and it has net margins of 12.2%.
Key information
52.3%
Earnings growth rate
49.2%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 19.9% |
| Return on equity | 28.2% |
| Net Margin | 12.2% |
| Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
Insulet Corporation's (NASDAQ:PODD) Earnings Haven't Escaped The Attention Of Investors
Apr 14
Estimating The Fair Value Of Insulet Corporation (NASDAQ:PODD)
Mar 31Insulet: Insulating Patients, Investors Still Have To Wait
Mar 28Insulet (NASDAQ:PODD) Is Doing The Right Things To Multiply Its Share Price
Feb 19Is Insulet Corporation (NASDAQ:PODD) Potentially Undervalued?
Jan 22Insulet: An Interesting, Yet Expensive, Story
Jan 10Is Insulet (NASDAQ:PODD) Using Too Much Debt?
Jan 09Insulet Corporation's (NASDAQ:PODD) Earnings Haven't Escaped The Attention Of Investors
Dec 27Estimating The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)
Nov 14Insulet (NASDAQ:PODD) Shareholders Will Want The ROCE Trajectory To Continue
Oct 31We Think Insulet (NASDAQ:PODD) Is Taking Some Risk With Its Debt
Oct 01Is There Now An Opportunity In Insulet Corporation (NASDAQ:PODD)?
Sep 16Estimating The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)
Aug 14Insulet (NASDAQ:PODD) Might Have The Makings Of A Multi-Bagger
Jul 31Is Insulet (NASDAQ:PODD) Using Too Much Debt?
Jun 18Getting In Cheap On Insulet Corporation (NASDAQ:PODD) Might Be Difficult
May 22Insulet (NASDAQ:PODD) Might Have The Makings Of A Multi-Bagger
Apr 30Here's Why Insulet (NASDAQ:PODD) Has A Meaningful Debt Burden
Jan 24Insulet (NASDAQ:PODD) Shareholders Will Want The ROCE Trajectory To Continue
Dec 28Insulet: An Overpriced Play In The Medical Space
Oct 18Insulet (NASDAQ:PODD) Has A Pretty Healthy Balance Sheet
Oct 02Insulet automated insulin delivery system Omnipod 5 gets CE mark
Sep 20The Return Trends At Insulet (NASDAQ:PODD) Look Promising
Sep 05Insulet wins FDA nod to use insulin delivery system in 2 – 5-year-olds
Aug 22Insulet: Bullish Factors For Portfolio Inclusion
Jul 23Insulet to pay $20M to Roche in patent settlement
Jul 11Returns On Capital Are Showing Encouraging Signs At Insulet (NASDAQ:PODD)
Jun 06Revenue & Expenses BreakdownBeta
How Insulet makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,697 | 206 | 708 | 205 |
| 30 Sep 23 | 1,557 | 120 | 669 | 213 |
| 30 Jun 23 | 1,465 | 63 | 628 | 200 |
| 31 Mar 23 | 1,368 | 1 | 597 | 187 |
| 31 Dec 22 | 1,305 | 5 | 588 | 180 |
| 30 Sep 22 | 1,243 | 17 | 538 | 173 |
| 30 Jun 22 | 1,178 | 35 | 515 | 165 |
| 31 Mar 22 | 1,142 | 45 | 484 | 163 |
| 31 Dec 21 | 1,099 | 17 | 466 | 160 |
| 30 Sep 21 | 1,037 | -29 | 474 | 157 |
| 30 Jun 21 | 996 | -30 | 446 | 158 |
| 31 Mar 21 | 959 | 9 | 411 | 152 |
| 31 Dec 20 | 904 | 7 | 384 | 147 |
| 30 Sep 20 | 868 | 29 | 334 | 144 |
| 30 Jun 20 | 826 | 18 | 320 | 137 |
| 31 Mar 20 | 777 | 5 | 315 | 135 |
| 31 Dec 19 | 738 | 12 | 298 | 132 |
| 30 Sep 19 | 694 | 17 | 270 | 126 |
| 30 Jun 19 | 653 | 17 | 268 | 117 |
| 31 Mar 19 | 600 | 14 | 251 | 103 |
| 31 Dec 18 | 564 | 3 | 248 | 95 |
| 30 Sep 18 | 529 | -13 | 249 | 80 |
| 30 Jun 18 | 500 | -17 | 227 | 78 |
| 31 Mar 18 | 486 | -23 | 218 | 77 |
| 31 Dec 17 | 464 | -27 | 209 | 76 |
| 30 Sep 17 | 437 | -29 | 191 | 72 |
| 30 Jun 17 | 410 | -30 | 179 | 65 |
| 31 Mar 17 | 387 | -26 | 168 | 60 |
| 31 Dec 16 | 367 | -27 | 166 | 56 |
| 30 Sep 16 | 347 | -34 | 159 | 53 |
| 30 Jun 16 | 324 | -49 | 156 | 49 |
| 31 Mar 16 | 297 | -62 | 149 | 48 |
| 31 Dec 15 | 264 | -62 | 139 | 43 |
| 30 Sep 15 | 253 | -51 | 129 | 38 |
| 30 Jun 15 | 256 | -44 | 126 | 35 |
| 31 Mar 15 | 268 | -56 | 128 | 29 |
| 31 Dec 14 | 231 | -48 | 108 | 28 |
| 30 Sep 14 | 285 | -49 | 112 | 27 |
| 30 Jun 14 | 271 | -59 | 115 | 26 |
| 31 Mar 14 | 259 | -40 | 108 | 24 |
| 31 Dec 13 | 247 | -45 | 117 | 22 |
| 30 Sep 13 | 236 | -53 | 116 | 21 |
| 30 Jun 13 | 230 | -44 | 106 | 22 |
Quality Earnings: PODD has high quality earnings.
Growing Profit Margin: PODD's current net profit margins (12.2%) are higher than last year (0.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PODD has become profitable over the past 5 years, growing earnings by 52.3% per year.
Accelerating Growth: PODD's earnings growth over the past year (4384.8%) exceeds its 5-year average (52.3% per year).
Earnings vs Industry: PODD earnings growth over the past year (4384.8%) exceeded the Medical Equipment industry 3.3%.
Return on Equity
High ROE: Whilst PODD's Return on Equity (28.16%) is high, this metric is skewed due to their high level of debt.